Document is current
Any future updates will be listed below
-
Authors
Benjamin, Kynon J. M. https://orcid.org/0000-0003-2016-4646
Chen, Qiang
Eagles, Nicholas J. https://orcid.org/0000-0002-9808-5254
Huuki-Myers, Louise A. https://orcid.org/0000-0001-5148-3602
Collado-Torres, Leonardo
Stolz, Joshua M.
Pertea, Geo https://orcid.org/0000-0002-3210-7182
Shin, Joo Heon https://orcid.org/0000-0002-5563-8605
Paquola, Apuã C. M. https://orcid.org/0000-0002-1329-6870
Hyde, Thomas M. https://orcid.org/0000-0002-8746-3037
Kleinman, Joel E. https://orcid.org/0000-0002-4210-6052
Jaffe, Andrew E.
Han, Shizhong https://orcid.org/0000-0002-5114-6742
Weinberger, Daniel R. https://orcid.org/0000-0003-2409-2969
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Minority Health and Health Disparities (K99MD016964)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH123183, R01MH121394, R01MH112751)
- License Information
-
More Information
Article History
Received: 26 May 2023
Accepted: 29 March 2024
First Online: 20 May 2024
Competing interests
: A.E.J. is currently an employee and shareholder of Neumora Therapeutics, which is unrelated to the contents of this manuscript. D.R.W. serves on the scientific advisory boards of Sage Therapeutics and Pasithea Therapeutics. J.E.K. is a member of a drug monitoring committee for an antipsychotic drug trial for Merck. The other authors declare no competing interests.
